Amgen Inc Investor Meeting at ASCO20 Virtual Scientific Program Transcript
My name is Ian, and I will be your conference facilitator today for Amgen's conference call in conjunction with the ASCO 2020 Virtual Scientific Program. (Operator Instructions)
I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.
Thanks, Ian. Good afternoon, everybody. Thanks for joining us. Would have been great to see you all in person as we normally do at ASCO, but given this year's virtual format, I'm glad that at least we have an opportunity to connect virtually.
So we have presented some important data at this year's ASCO, particularly on AMG 510, or sotorasib, as we now call it, which is our novel small molecule inhibitor of KRAS G12C. Now one portion of the study known as CodeBreaK 100 relates to activity in advanced colorectal cancer patients, and the other is Phase I data in patients with advanced solid tumors other than non-small cell lung cancer and colorectal cancer. We also presented some updated results from a Phase I dose escalation
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
